Jonathan Busquets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan Busquets has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Mu-Jie Lu
Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
2 shared publications - Stefano Tiziani
Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX
2 shared publications - Valeria Impedovo
Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX
2 shared publications - William Matsui
University of Texas at Austin, Austin, TX
2 shared publications - Xiaolu Ang Cambronne
Department of Molecular Biosciences, The University of Texas at Austin, Austin, USA
2 shared publications - Yu-Tai Chang
Department of Molecular and Cellular Biology, University of California, Davis, CA 95616, USA
2 shared publications
Latest Publications
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 4 (3_Suppleme) , A42
Abstract A42: SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Citation Format: Mu-Jie Lu, Jonathan Busquets, Valeria Impedovo, Yu-Tai Chang, William Matsui, Stefano Tiziani, Xiaolu Cambronne. SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A42.
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 4 (3_Suppleme) , A42
Open AccessAbstract A42: SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Citation Format: Mu-Jie Lu, Jonathan Busquets, Valeria Impedovo, Yu-Tai Chang, William Matsui, Stefano Tiziani, Xiaolu Cambronne. SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A42.
- Open Access
SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD + into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Statement of significance: This investigation describes an approach to directly modulate the tricarboxylic acid cycle as a potential vulnerability in oxidative tumors. Using AML models, the work is an inaugural look into SLC25A51’s role supporting oxidative mitochondrial metabolism and identifies SLC25A51 levels as a potential marker for stratification of AML.
Open AccessSLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD + into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Statement of significance: This investigation describes an approach to directly modulate the tricarboxylic acid cycle as a potential vulnerability in oxidative tumors. Using AML models, the work is an inaugural look into SLC25A51’s role supporting oxidative mitochondrial metabolism and identifies SLC25A51 levels as a potential marker for stratification of AML.
- 1 July 2019
- Published by American Association for Cancer Research (AACR)
- Vol. 79 (13 Supplem) , 3320
Abstract 3320: Dietary inflammatory potential in relation to the gut microbiome among persons at varied risk of colorectal neoplasia
Purpose: Diet modulates gut microbiome composition and systemic inflammation—both intermediary factors in the development of colorectal neoplasia. We investigated the association of total dietary inflammatory potential, as assessed by the literature-derived dietary inflammatory index (DII®), with gut microbiota diversity and composition, microbial gene pathways, and circulating markers. Methods: This epidemiological study was comprised of 36 cancer-free colonoscopy patients (79% positive for precancerous polyps) and 65 healthy volunteers from the medical center community (N=101). Participants completed dietary assessments and provided stool samples for 16S rDNA sequencing >1 month after colonoscopy/polyp removal or antibiotic use. In a subset (n=47), we conducted whole genome shotgun (WGS) sequencing and collected a fasting blood sample. Energy-adjusted (E)-DII score was calculated for each subject and categorized into tertiles. The association between E-DII and fecal microbiota alpha- and beta-diversity was examined. Linear discriminant analysis Effect Size (LEfSe) was used to identify differentially abundant taxa by E-DII level. Multiple linear regression models were used to examine associations controlled for confounders. Results from the least absolute shrinkage and selection operator (LASSO) method and Spearman’s correlation were used to select and evaluate associations of bacterial species with E-DII, their functional pathways, and circulating markers. Results: We observed large between-person variation in Bacteroidaceae and Enterobacteriaceae, two dominant bacteria in the overall sample. Neither alpha- nor beta-diversity significantly differed across E-DII levels. Ruminococcus torques, Acidaminococcus intestine, and Clostridium leptum were most abundant in the most pro-inflammatory diet group, while Akkermansia muciniphila was enriched among subjects with the most anti-inflammatory diet. In the WGS subset, Luteimonas mephitis was inversely associated with E-DII, circulating Lipocalin-2 (r=-0.34; P=0.02), and plasminogen activator inhibitor-1 (r=-0.29; P=0.05). Akkermansia muciniphilaappeared to be inversely correlated with monocyte chemoattractant protein-1 (r=-0.26; P=0.09). Two microbial pathways inversely associated with E-DII, AMP-activated protein kinase (AMPK) and carbon metabolism, were also inversely correlated with C-peptide (AMPK: r=-0.35, P= 0.02; carbon: r=-0.30, P=0.04). Conclusions: Dietary inflammatory potential was associated with differential composition of specific microbes, but not overall diversity of the gut microbiome. Species associated with E-DII were similarly associated with circulating inflammatory biomarkers. Microbial AMPK signaling and carbon metabolism pathways may underlie diet-microbiota interactions that modulate systemic inflammation. Citation Format: Jiali Zheng, Kristi L. Hoffman, Nitin Shivappa, Jonathan Busquets, Jiun-Sheng Chen, Samir Hanash, Susan Schembre, James Hébert, Joseph Petrosino, Peng Wei, Carrie R. Daniel. Dietary inflammatory potential in relation to the gut microbiome among persons at varied risk of colorectal neoplasia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3320.
- 1 July 2019
- Published by American Association for Cancer Research (AACR)
- Vol. 79 (13 Supplem) , 3320
Abstract 3320: Dietary inflammatory potential in relation to the gut microbiome among persons at varied risk of colorectal neoplasia
Purpose: Diet modulates gut microbiome composition and systemic inflammation—both intermediary factors in the development of colorectal neoplasia. We investigated the association of total dietary inflammatory potential, as assessed by the literature-derived dietary inflammatory index (DII®), with gut microbiota diversity and composition, microbial gene pathways, and circulating markers. Methods: This epidemiological study was comprised of 36 cancer-free colonoscopy patients (79% positive for precancerous polyps) and 65 healthy volunteers from the medical center community (N=101). Participants completed dietary assessments and provided stool samples for 16S rDNA sequencing >1 month after colonoscopy/polyp removal or antibiotic use. In a subset (n=47), we conducted whole genome shotgun (WGS) sequencing and collected a fasting blood sample. Energy-adjusted (E)-DII score was calculated for each subject and categorized into tertiles. The association between E-DII and fecal microbiota alpha- and beta-diversity was examined. Linear discriminant analysis Effect Size (LEfSe) was used to identify differentially abundant taxa by E-DII level. Multiple linear regression models were used to examine associations controlled for confounders. Results from the least absolute shrinkage and selection operator (LASSO) method and Spearman’s correlation were used to select and evaluate associations of bacterial species with E-DII, their functional pathways, and circulating markers. Results: We observed large between-person variation in Bacteroidaceae and Enterobacteriaceae, two dominant bacteria in the overall sample. Neither alpha- nor beta-diversity significantly differed across E-DII levels. Ruminococcus torques, Acidaminococcus intestine, and Clostridium leptum were most abundant in the most pro-inflammatory diet group, while Akkermansia muciniphila was enriched among subjects with the most anti-inflammatory diet. In the WGS subset, Luteimonas mephitis was inversely associated with E-DII, circulating Lipocalin-2 (r=-0.34; P=0.02), and plasminogen activator inhibitor-1 (r=-0.29; P=0.05). Akkermansia muciniphilaappeared to be inversely correlated with monocyte chemoattractant protein-1 (r=-0.26; P=0.09). Two microbial pathways inversely associated with E-DII, AMP-activated protein kinase (AMPK) and carbon metabolism, were also inversely correlated with C-peptide (AMPK: r=-0.35, P= 0.02; carbon: r=-0.30, P=0.04). Conclusions: Dietary inflammatory potential was associated with differential composition of specific microbes, but not overall diversity of the gut microbiome. Species associated with E-DII were similarly associated with circulating inflammatory biomarkers. Microbial AMPK signaling and carbon metabolism pathways may underlie diet-microbiota interactions that modulate systemic inflammation. Citation Format: Jiali Zheng, Kristi L. Hoffman, Nitin Shivappa, Jonathan Busquets, Jiun-Sheng Chen, Samir Hanash, Susan Schembre, James Hébert, Joseph Petrosino, Peng Wei, Carrie R. Daniel. Dietary inflammatory potential in relation to the gut microbiome among persons at varied risk of colorectal neoplasia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3320.